Valiant Organics
Limited

August 12, 2026

To,
Listing / Compliance Department
BSE LTD
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400 001
SCRIP CODE – 540145

To,
Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G Block Bandra-Kurla Complex,
Bandra (E), Mumbai- 400 051.
SYMBOL- VALIANTORG

Sub: Outcome of the Board Meeting

Ref: Regulation 33 and 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations")

Dear Sir / Madam,

Pursuant to Regulation 33 and 30 read with Para A, Part A of Schedule III of the SEBI Listing Regulations, as amended, we wish to inform you that the Board of Directors at its Meeting held today i.e. **Wednesday, August 12, 2026**, inter-alia considered and approved :-

1. The Unaudited Standalone and Consolidated Financial Results ("Financial Results") for the quarter ended June 30, 2026, based on the recommendation of the Audit Committee, in this regard we enclosed the following as an **Annexure A**:

- Statement showing the Financial Results; and
- Limited Review Report of the Statutory Auditors

Further, please note that the Company has already made necessary arrangement to publish the Financial Results in the Newspapers as required under Regulation 47 of the SEBI Listing Regulations.

2. Re-appointment of **Shri Sathiababu K. Kallada** (DIN: 02107652) as the **Managing Director** of the Company for a term of 3 (Three) years with effect from May 24, 2027 to May 23, 2030, based on recommendation of Nomination and Remuneration Committee and subject to the further approval of the Shareholders of the Company in the ensuing Annual General Meeting.

We hereby confirm that Shri Sathiababu K. Kallada is not debarred from holding the office of Director pursuant to any order of SEBI or such other authority.

The required details pursuant to SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on January 30, 2026, are annexed herewith as **Annexure-B**.

3. The shifting of Registered Office of the Company from 109, 1st Floor, Udyog Kshetra, Mulund Goregaon Link Road, Mulund (W) – 400080, to Plot No. M-7, MIDC, Tarapur, Boisar, Palghar – 401506, Maharashtra, India, subject to the approval of Shareholders of the Company in the ensuing Annual General Meeting. This relocation also involves a change in jurisdiction from the Registrar of

Valiant Organics
Limited

Companies, Mumbai I to the Registrar of Companies, Mumbai II (headquartered at Navi-Mumbai), within the State of Maharashtra.

In addition to the above, we wish to inform you that, the **Corporate Office** of the Company is now located at **701-A, Tower-B, Embassy 247 Park, Gandhi Nagar, Vikhroli (West), Mumbai – 400083, Maharashtra**, from where the administrative and other corporate functions of the Company shall be carried out.

The Meeting of the Board of Directors commenced at 12.35 PM (IST) and concluded at 03.50 PM (IST).

Kindly take the same on your record.

Thanking You,

Yours faithfully,
For **Valiant Organics Limited**

Kaustubh Bhalchandra Kulkarni
Digitally signed by Kaustubh Bhalchandra Kulkarni
Date: 2026.08.12 16:08:38 +05'30'

Kaustubh Kulkarni
Company Secretary
ICSI M No: A52980

Encl.: a/a

gokhale & sathe
(regd.)
chartered accountants

304/308/309/311,udyog mandir no.1,
7-c, bhagoji keer marg,mahim,
mumbai - 400 016,maharashtra,india.

Independent Auditor's Limited Review Report on Unaudited Standalone Financial Results of Valiant Organics Limited for the Quarter Ended 30 June 2026 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
Valiant Organics Limited.

1 We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Valiant Organics Limited ('the Company') for the quarter ended 30 June 2026 being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 as amended ("Listing Regulations).

2 This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

GOKHALE & SATHE
MUMBAI
FIRM No. 103264W
CHARTERED ACCOUNTANTS

tel.(off). : +91 022 4348 4242 I **email :** office@gokhalesathe.in

4 Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

5 Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year-to-date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year were subject to limited review by us.

For Gokhale & Sathe,
Chartered Accountants,
ICAI Firm Registration No.: 103264W

GOKHALE & SATHE
MUMBAI
FIRM No. 103264W
CHARTERED ACCOUNTANTS

Ravindra More
Partner
ICAI Membership No.: 153666
UDIN: 26153666IGMKCS8423

Date: 12 August 2026
Place: Mumbai

Valiant Organics Limited

Valiant Organics Limited

Addresss - 109, Udyog Kshetra, 1st Floor, Mulund Goregaon Link Road, Mulund (W), Mumbai - 400 080.

CIN :- L24230MH2005PLC151348

ANNEXURE I

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June,2026

Rs. In Lakhs (except EPS)

Sr.	Particulars	Standalone			
		Quarter Ended			Year Ended
		30-Jun-2026	31-Mar-2026	30-Jun-2025	31-Mar-2026
		(Reviewed)	(Audited)	(Reviewed)	(Audited)
1	**Income**				
a)	Revenue from Operations	23,153.85	21,770.02	20,440.64	73,838.31
b)	Other Income	264.20	400.97	107.42	691.48
	Total Income	**23,418.05**	**22,170.99**	**20,548.06**	**74,529.79**
2	**Expenses**				
a)	Cost of Materials consumed	15,032.08	12,174.24	12,545.95	44,126.75
b)	Purchases of stock in Trade	20.25	51.23	14.35	193.64
c)	Changes in inventories of Finished Goods, WIP & Stock-In-Trade	(1,678.97)	1,090.66	18.88	(621.64)
d)	Employee benefit expenses	1,311.40	1,332.68	1,185.66	4,885.69
e)	Finance Cost	512.93	329.79	604.57	1,819.91
f)	Depreciation, Amortization and impairment Expense	1,021.97	1,025.23	941.70	3,956.50
g)	Other expenses	4,306.69	4,472.25	4,188.65	16,435.15
	Total Expenses	**20,526.35**	**20,476.07**	**19,499.76**	**70,795.98**
3	**Profit/(Loss) before exceptional item & tax (1- 2)**	**2,891.70**	**1,694.91**	**1,048.30**	**3,733.81**
4	Exceptional Items (Gain/ (Loss))(Refer Note No. 6)	-	-	-	572.08
5	**Profit/ (Loss) before tax (3-4)**	**2,891.70**	**1,694.91**	**1,048.30**	**4,305.89**
6	Tax expense (Net)				
a)	Current Year Tax	-	-	-	-
b)	Short / (Excess) Provision for Tax of Previous Years	-	(253.17)	-	(253.17)
c)	Deferred Tax	709.43	436.34	290.46	1,123.50
	Total Tax expense (Net)	**709.43**	**183.17**	**290.46**	**870.33**
7	**Net Profit / (Loss) for the period (5-6)**	**2,182.27**	**1,511.74**	**757.84**	**3,435.56**
8	**Other Comprehensive Income**				
	Item that will not to be reclassified to statement of Profit and Loss				
	Remeasurement of defined benefit Liability/Assets & Fair value changes on Investments	37.68	17.48	37.19	7.20
	Taxes on Remeasurement of defined benefit Liability/Assets & Fair value changes on Investments	(6.14)	(5.53)	(4.25)	(2.65)
	Total Other Comprehensive Income	**31.54**	**11.94**	**32.94**	**4.55**
9	**Total of profit and other comprehensive income for the year (7+8)**	**2,213.81**	**1,523.68**	**790.78**	**3,440.11**
10	**Other Equity excluding revaluation reserve**	-	-	-	**66,883.14**
11	**Profit attributable to :**				
	Owners of the Company	**2,182.27**	**1,511.74**	**757.84**	**3,435.56**
	Non- Controlling Interest	-	-	-	-
	Total Comprehensive Income attributable to :				
	Owners of the Company	**2,213.81**	**1,523.68**	**790.78**	**3,440.11**
	Non- Controlling Interest	-	-	-	-
12	Paid up equity share capital (face value of Rs.10 each)	2,803.46	2,801.96	2,800.46	2,801.96
	Earning per equity share (in Rs.)(not annualised in case of quarterly results)				
	(a) Basic	7.79	5.40	2.71	12.27
	(b) Diluted	7.79	5.39	2.71	12.26

Notes:

1 The above results for the Quarter ended June 2026 have been reviewed by the Audit Committee in their meeting held on 12th August, 2026 and approved by the Board of Directors in their meeting held on 12th August, 2026.

2 Based on the internal reports reviewed by the Chief Operating Decision Maker (CODM) of the Company, the Pharma Business has been identified as an additional reportable segment, along with the existing reportable segment, namely 'Specialty Chemicals', in accordance with the requirements of Ind AS 108 - Operating Segments. (Refer Annexure No. 1 and 2 for Segment Information)

3 During the quarter ended 31st December, 2025, 15,000 equity shares of face value Rs. 10/- each were allotted to eligible employee on 29th November, 2025, pursuant to the Valiant Employees Stock Option Plan, 2022.

4 During the quarter ended 30th June, 2026, 15,000 equity shares of face value Rs. 10/- each were allotted to eligible employee on 22nd June, 2026, pursuant to the Valiant Employees Stock Option Plan, 2022.

5 Till date the company has granted 1000 and 19500 stock options to its eligible employees on 13th Nov 2025 and 16th May 2026 respectively, pursuant to the Valiant Employees Stock Option Plan, 2022, after obtaining the approval of the Nomination and Remuneration Committee

6 In FY 25-26, the Company has received Rs. 852.76 lakhs towards fire insurance claim settlement (material damage and loss of profit) relating to the Sarigam Division fire incident in FY 2022-23. Out of the same, Rs. 572.08 lakhs has been recognised under Exceptional Items during the period and the balance has been appropriately accounted for in the financial statements.

7 The Company has following Subsidiaries and Associate Entities for the purpose of Consolidated Financials:-
1. Dhanvallabh Ventures LLP (Subsidiary of Valiant Organics Limited)
2. Valiant Speciality Chemicals Limited (Wholly owned Subsidiary of Valiant Organics Limited)
3. Valiant Laboratories Limited (Associate Company through Dhanvallabh Ventures LLP)
4. Valiant Advanced Sciences Private Limited (Step-Down Subsidiary of Valiant Laboratories Limited)

8 Pursuant to the criteria prescribed under Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dhanvallabh Ventures LLP (DVLLP) a subsidiary of the Company, has been identified as a "Material Subsidiary" of the Company for FY 2026-27, based on DVLLP's financial position of DVLLP as at March 31, 2026.

9 The company has entered into Conducting cum Loan & License Agreement with Aarti Pharmalabs Ltd (Related Party) for conducting manufacturing operations on behalf of Aarti Pharmalabs Limited at its AJ4 division w.e.f 15th May 2025 as per terms and conditions of the said agreement.

10 The aforesaid unaudited Financial results will be uploaded on the company's website www.valiantorganics.com and will also be available on the websites of BSE Limited i.e. www.bseindia.com / NSE Limited i.e www.nseindia.com.

11 Figures for the previous period have been regrouped or rearranged wherever necessary.

Place : Mumbai
Date - 12th August 2026

GOKHALE & SATHE MUMBAI FIRM No. 103264W CHARTERED ACCOUNTANTS

VALIANT ORGANICS LTD. MUMBAI

Mr. Parimal H. Desai
Managing Director
DIN: 00009272

VALIANT ORGANICS LIMITED
Standalone Segment-wise Information
for the Quarter ended 30th June, 2026

(₹ In Lakh)

Particulars	STANDALONE			
	3 Months ended	3 Months ended	3 Months ended	12 Months ended
	30-Jun-2026	31-Mar-2026	30-Jun-2025	31-Mar-2026
	(Reviewed)	(Audited)	(Reviewed)	(Audited)
1. Segment Revenue				
a) Speciality Chemical Division	17,573.67	16,947.11	15,068.63	57,481.94
b) Pharma Division	5,580.19	4,822.91	5,372.00	16,356.38
Total	**23,153.85**	**21,770.02**	**20,440.64**	**73,838.31**
Gross Revenue from sale of products and services	**23,153.85**	**21,770.02**	**20,440.64**	**73,838.31**
2. Segment Results before Interest and Tax				
a) Speciality Chemical Division	2,505.53	2,141.27	1,736.01	6,025.06
b) Pharma Division	899.10	(116.57)	(83.13)	(471.34)
Total	**3,404.63**	**2,024.70**	**1,652.88**	**5,553.72**
Less : i) Finance Costs	512.93	329.79	604.58	1,819.91
ii) Other un-allocable (income) net of un-allocable expenditure	-	-	-	-
iii) Exceptional items	-	-	-	572.08
Profit Before Tax	**2,891.70**	**1,694.91**	**1,048.30**	**4,305.89**
3. Segment Assets				
a) Speciality Chemical Division	72,293.48	67,058.56	64,215.94	67,058.56
b) Pharma Division	46,687.84	45,898.90	44,259.71	45,898.90
Total	**1,18,981.32**	**1,12,957.46**	**1,08,475.65**	**1,12,957.46**
Unallocated Corporate Assets	403.52	128.02	1,216.51	128.02
Total Assets	**1,19,384.84**	**1,13,085.48**	**1,09,692.16**	**1,13,085.48**
4. Segment Liabilities				
a) Speciality Chemical Division	27,560.36	26,559.87	35,449.53	26,559.87
Pharma Division	14,324.04	11,960.28	3,525.85	11,960.28
Total	**41,884.40**	**38,520.15**	**38,975.38**	**38,520.15**
Unallocated Corporate Liabilities	77,500.44	74,565.33	70,716.78	74,565.33
Total Liabilities	**1,19,384.84**	**1,13,085.48**	**1,09,692.16**	**1,13,085.48**

GOKHALE & SATHE MUMBAI CHARTERED ACCOUNTANTS FIRM No. 103264W

VALIANT ORGANICS LTD. MUMBAI

Place : Mumbai

Date - 12th August 2026

P.H.Desai

Mr. Parimal H. Desai

Managing Director

DIN: 00009272

gokhale & sathe
(regd.)
chartered accountants
304/308/309/311,udyog mandir no.1,
7-c, bhagoji keer marg,mahim,
mumbai - 400 016,maharashtra,india.

Independent Auditor's Limited Review Report on Unaudited Consolidated Financial Results of Valiant Organics Limited for the Quarter Ended 30 June 2026 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
Valiant Organics Limited.

1 We have reviewed the accompanying statement of unaudited consolidated financial results of Valiant Organics Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (the Holding Company, its subsidiaries and associate companies together referred to as 'the Group') for the quarter ended 30 June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2 This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

GOKHALE & SATHE
MUMBAI
FIRM No. 103264W
CHARTERED ACCOUNTANTS

4 This statement includes the results of the following entities:

a) Subsidiaries:

(i) Valiant Speciality Chemical Limited (Wholly Owned Subsidiary of Valiant Organics Limited);

(ii) Dhanvallabh Ventures LLP (Subsidiary of Valiant Organics Limited).

b) Associate Companies:

(i) Valiant Laboratories Limited (Associate Company through Dhanvallabh Ventures LLP);

(ii) Valiant Advanced Sciences Private Limited (Step-Down Subsidiary of Valiant Laboratories Limited).

5 Based on our review and procedures performed as stated in paragraph 3 above and based on consideration of the limited review reports of the auditors referred in paragraph no 7 and 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

6 Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year-to-date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year were subject to limited review by us.

7 We did not review the interim financial statements of one of subsidiary entity included in the statement of unaudited consolidated financial results, whose audited financial statements reflect total revenue from operations of Rs. Nil lakhs and total net profit after tax of Rs. 78.69 lakhs for the quarter ended 30 June 2026, as considered in the Statement. This financial information has been audited by other auditors whose audit report has been furnished to us by the management

GOKHALE & SATHE MUMBAI FIRM No. 103264W CHARTERED ACCOUNTANTS and our conclusion on the Statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the report of other auditors and the procedures performed by us as stated in paragraph 3 above.

8 We did not review the interim financial statements of one of the subsidiary company included in the statement of unaudited consolidated financial results, whose unaudited financial statements reflect total revenue from operations of Rs. Nil lakhs and total net loss after tax of Rs. 0.05 lakhs for the quarter ended 30 June 2026, as considered in the Statement. This financial information has been reviewed by other auditors whose review report has been furnished to us by the management and our conclusion on the Statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the report of other auditors and the procedures performed by us as stated in paragraph 3 above.

9 We did not review the interim financial statements of one indirect associate company (including its wholly owned subsidiary) whose share of profit of Rs. 722.99 Lakhs included in the statement of unaudited consolidated financial results for the quarter ended 30 June 2026. This financial information has been audited by other auditors whose audit reports has been furnished to us by the management and our conclusion on the Statements, in so far as it relates to the amounts and disclosures included in respect of this indirect associate (including its wholly owned subsidiary) is based solely on the report of other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of such matter.

For Gokhale & Sathe,
Chartered Accountants,
ICAI Firm Registration No: 103264W

GOKHALE & SATHE
MUMBAI
FIRM No. 103264W
CHARTERED ACCOUNTANTS

Ravindra More
Partner
ICAI Membership No: 153666
UDIN: 26153666MIXGKF3671

Date: 12 August 2026
Place: Mumbai

Valiant Organics Limited

Valiant Organics Limited

Addresss - 109, Udyog Kshetra, 1st Floor, Mulund Goregaon Link Road, Mulund (W), Mumbai - 400 080.
CIN :- L24230MH2005PLC151348

ANNEXURE I

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June,2026

Rs. In Lakhs (except EPS)

No.	Particulars	Consolidation			
		Quarter Ended			Year Ended
		30-Jun-2026 (Reviewed)	31-Mar-2026 (Audited)	30-Jun-2025 (Reviewed)	31-Mar-2026 (Audited)
1	**Income**				
a)	**Revenue from Operations**	23,153.85	21,777.71	20,440.64	73,875.87
b)	Other Income	327.75	400.97	107.72	691.99
	Total Income	**23,481.61**	**22,178.67**	**20,548.36**	**74,567.86**
2	**Expenses**				
a)	Cost of Materials consumed	15,032.08	12,181.83	12,545.95	44,165.62
b)	Purchases of stock in Trade	20.25	51.23	14.35	193.64
c)	Changes in inventories of Finished Goods, WIP & Stock-In-Trade	(1,678.97)	1,090.66	18.88	(621.64)
d)	Employee benefit expenses	1,311.40	1,332.68	1,185.66	4,885.69
e)	Finance Cost	512.93	329.79	604.62	1,819.91
f)	Depreciation, Amortization and impairment Expense	1,021.97	1,025.23	941.70	3,956.50
g)	Other expenses	4,306.85	4,472.71	4,188.84	16,434.82
	Total Expenses	**20,526.50**	**20,484.13**	**19,500.00**	**70,834.52**
3	**Profit/(Loss) before exceptional item & tax (1- 2)**	**2,955.10**	**1,694.55**	**1,048.36**	**3,733.35**
4	Share of Profit/(Loss) of Associates	**722.99**	**60.55**	**62.38**	**(111.96)**
5	Exceptional Items (Gain/ (Loss))(Refer Note No. 6)	-	-	-	**572.08**
6	**Profit/ (Loss) before tax (3 - 4 -5)**	**3,678.09**	**1,755.10**	**1,110.74**	**4,193.47**
7	**Tax expense (Net)**				
a)	Current Year Tax	42.32	-	-	0.29
b)	Short /(Excess) Provision for Tax of Previous Years	-	(253.17)	-	(253.17)
c)	Deferred Tax	709.43	436.34	290.46	1,123.50
	Total Tax expense (Net)	**751.75**	**183.17**	**290.46**	**870.62**
8	**Net Profit / (Loss) for the period (6-7)**	**2,926.33**	**1,571.92**	**820.28**	**3,322.85**
9	**Other Comprehensive Income**				
	Item that will not to be reclassified to statement of Profit and Loss				
	Remeasurement of defined benefit Liability/Assets & Fair value changes on Investments	37.68	17.48	37.19	7.20
	Taxes on Remeasurement of defined benefit Liability/Assets & Fair value changes on Investments	(6.14)	(5.53)	(4.25)	(2.65)
	Total Other Comprehensive Income	**31.54**	**11.95**	**32.94**	**4.55**
10	**Total of profit and other comprehensive income for the year (8+9)**	**2,957.88**	**1,583.86**	**853.23**	**3,327.40**
11	**Other Equity excluding revaluation reserve**	-	-	-	**73,136.06**
12	**Profit attributable to :**				
	Owners of the Company	2,905.21	1,572.06	820.32	3,323.57
	Non- Controlling Interest	21.13	(0.14)	(0.04)	(0.72)
	Total Comprehensive Income attributable to :				
	Owners of the Company	2,936.75	1,584.01	853.26	3,328.12
	Non- Controlling Interest	21.13	(0.14)	(0.04)	(0.72)
13	Paid up equity share capital (face value of Rs.10 each)	2,803.46	2,801.96	2,800.46	2,801.96
	Earning per equity share (in Rs.)(not annualised in case of quarterly results)				
	(a) Basic	10.44	5.61	2.93	11.86
	(b) Diluted	10.44	5.61	2.93	11.86

Place : Mumbai
Date - 12th August 2026

GOKHALE & SATHE MUMBAI FIRM No. 103264W CHARTERED ACCOUNTANTS

VALIANT ORGANICS LTD. MUMBAI

P.H.Desai
Mr. Parimal H. Desai
Managing Director
DIN: 00009272

VALIANT ORGANICS LIMITED
Consolidated Segment-wise Information
for the Quarter ended 30th June, 2026

Particulars			CONSOLIDATED 3 Months ended 30-Jun-2026 (Reviewed)	3 Months ended 31-Mar-2026 (Audited)	3 Months ended 30-Jun-2025 (Reviewed)	12 Months ended 31-Mar-2026 (Audited)
1.	**Segment Revenue**					
	a)	Speciality Chemical Division	17,573.67	16,947.11	15,068.63	57,481.94
	b)	Pharma Division	5,580.19	4,830.60	5,372.00	16,393.94
		Total	**23,153.85**	**21,777.71**	**20,440.64**	**73,875.87**
Gross Revenue from sale of products and services			**23,153.85**	**21,777.71**	**20,440.64**	**73,875.87**
2.	**Segment Results before Interest and Tax**					
	a)	Speciality Chemical Division	2,505.53	2,141.27	1,736.01	6,025.06
	b)	Pharma Division	1,685.48	(56.39)	(20.64)	(583.77)
		Total	**4,191.02**	**2,084.88**	**1,715.37**	**5,441.29**
	Less : i)	Finance Costs	512.93	329.79	604.62	1,819.91
	ii)	Other un-allocable (income) net of un-allocable expenditure	-	-	-	-
	iii)	Exceptional items	-	-	-	572.08
Profit Before Tax			**3,678.09**	**1,755.10**	**1,110.74**	**4,193.47**
3.	**Segment Assets**					
	a)	Speciality Chemical Division	72,293.48	67,058.56	64,215.94	67,058.56
	b)	Pharma Division	55,263.49	55,841.42	54,599.21	55,841.42
		Total	**1,27,556.98**	**1,22,899.98**	**1,18,815.16**	**1,22,899.98**
		Unallocated Corporate Assets	432.79	179.44	1,874.74	179.44
Total Assets			**1,27,989.77**	**1,23,079.42**	**1,20,689.90**	**1,23,079.42**
4.	**Segment Liabilities**					
	a)	Speciality Chemical Division	27,560.36	26,559.87	35,449.53	26,559.87
		Pharma Division	22,928.96	21,954.22	14,523.59	21,954.22
		Total	**50,489.32**	**48,514.09**	**49,973.12**	**48,514.09**
		Unallocated Corporate Liabilities	77,500.44	74,565.33	70,716.78	74,565.33
Total Liabilities			**1,27,989.77**	**1,23,079.42**	**1,20,689.90**	**1,23,079.42**

Place : Mumbai

Date - 12th August 2026

GOKHALE & SATHE MUMBAI FIRM No. 103264W CHARTERED ACCOUNTANTS

VALIANT ORGANICS LTD. MUMBAI

P H Desai

Mr. Parimal H. Desai
Managing Director
DIN: 00009272

Valiant Organics Limited

Annexure – B

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Details of Director
1.	**Name of Director**	**Shri Sathiababu K. Kallada (DIN: 02107652)**
2.	**Reason for Changes viz. ~~appointment,~~ re-appointment, ~~resignation, removal, death or otherwise;~~**	Re-appointment of Shri Sathiababu K. Kallada (DIN: 02107652) as a Managing Director of the Company.
3.	**Date of ~~appointment~~ / re - appointment / ~~cessation (as applicable)~~ & term of ~~appointment~~ / re - appointment;**	**Date of re-appointment-** Re-appointment is effective from May 24, 2027 up to May 23, 2030, on the terms and conditions prescribed in the Agreement to be entered into with him and subject to the approval of the Shareholders of the Company. **Terms of Re-appointment-** 3 (Three) consecutive years, NOT liable to Retire by Rotation.
4.	**Brief Profile (in case of appointment);**	Shri Sathiababu K. Kallada is a Bachelor of Science with more than 38 years of experience in the Chemical Industry. His experience has helped the Company emerge as one of the leading Speciality Chemicals Companies in the Country.
5.	**Disclosure of relationships between directors, (in case of appointment of a director);**	Shri Sathiababu K. Kallada is not related to any Director of the Company.